Literature DB >> 23650354

Dynamic vaccine blocks relapse to compulsive intake of heroin.

Joel E Schlosburg1, Leandro F Vendruscolo, Paul T Bremer, Jonathan W Lockner, Carrie L Wade, Ashlee A K Nunes, G Neil Stowe, Scott Edwards, Kim D Janda, George F Koob.   

Abstract

Heroin addiction, a chronic relapsing disorder characterized by excessive drug taking and seeking, requires constant psychotherapeutic and pharmacotherapeutic interventions to minimize the potential for further abuse. Vaccine strategies against many drugs of abuse are being developed that generate antibodies that bind drug in the bloodstream, preventing entry into the brain and nullifying psychoactivity. However, this strategy is complicated by heroin's rapid metabolism to 6-acetylmorphine and morphine. We recently developed a "dynamic" vaccine that creates antibodies against heroin and its psychoactive metabolites by presenting multihaptenic structures to the immune system that match heroin's metabolism. The current study presents evidence of effective and continuous sequestration of brain-permeable constituents of heroin in the bloodstream following vaccination. The result is efficient blockade of heroin activity in treated rats, preventing various features of drugs of abuse: heroin reward, drug-induced reinstatement of drug seeking, and reescalation of compulsive heroin self-administration following abstinence in dependent rats. The dynamic vaccine shows the capability to significantly devalue the reinforcing and motivating properties of heroin, even in subjects with a history of dependence. In addition, targeting a less brain-permeable downstream metabolite, morphine, is insufficient to prevent heroin-induced activity in these models, suggesting that heroin and 6-acetylmorphine are critical players in heroin's psychoactivity. Because the heroin vaccine does not target opioid receptors or common opioid pharmacotherapeutics, it can be used in conjunction with available treatment options. Thus, our vaccine represents a promising adjunct therapy for heroin addiction, providing continuous heroin antagonism, requiring minimal medical monitoring and patient compliance.

Entities:  

Keywords:  antinociception; immunotherapy; progressive ratio

Mesh:

Substances:

Year:  2013        PMID: 23650354      PMCID: PMC3670323          DOI: 10.1073/pnas.1219159110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine.

Authors:  D E Selley; C C Cao; T Sexton; J A Schwegel; T J Martin; S R Childers
Journal:  Biochem Pharmacol       Date:  2001-08-15       Impact factor: 5.858

2.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.

Authors:  Johan Kakko; Kerstin Dybrandt Svanborg; Mary Jeanne Kreek; Markus Heilig
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

3.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Changes in heroin self-administration by a rhesus monkey after morphine immunisation.

Authors:  K F Bonese; B H Wainer; F W Fitch; R M Rothberg; C R Schuster
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

5.  Efficient analysis of experimental observations.

Authors:  W J Dixon
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

Review 6.  Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose.

Authors:  Alison J Ritter
Journal:  Aust N Z J Psychiatry       Date:  2002-04       Impact factor: 5.744

7.  Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: an event-related fMRI study.

Authors:  Qiang Li; Yarong Wang; Yi Zhang; Wei Li; Weichuan Yang; Jia Zhu; Ning Wu; Haifeng Chang; Ying Zheng; Wei Qin; Liyan Zhao; Kai Yuan; Jixin Liu; Wei Wang; Jie Tian
Journal:  Brain Res       Date:  2012-06-30       Impact factor: 3.252

8.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

9.  Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat.

Authors:  G F Koob; H O Pettit; A Ettenberg; F E Bloom
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

10.  Naltrexone-induced dysphoria in former opioid addicts.

Authors:  T J Crowley; J E Wagner; G Zerbe; M Macdonald
Journal:  Am J Psychiatry       Date:  1985-09       Impact factor: 18.112

View more
  45 in total

1.  Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.

Authors:  Brooke E Schmeichel; Estelle Barbier; Kaushik K Misra; Candice Contet; Joel E Schlosburg; Dimitri Grigoriadis; John P Williams; Camilla Karlsson; Caleb Pitcairn; Markus Heilig; George F Koob; Leandro F Vendruscolo
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

3.  Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice.

Authors:  Guro Søe Eriksen; Jannike Mørch Andersen; Fernando Boix; Marianne Skov-Skov Bergh; Vigdis Vindenes; Kenner C Rice; Marilyn A Huestis; Jørg Mørland
Journal:  J Pharmacol Exp Ther       Date:  2016-06-08       Impact factor: 4.030

Review 4.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

5.  Pharmacotherapy: Quest for the quitting pill.

Authors:  Cassandra Willyard
Journal:  Nature       Date:  2015-06-25       Impact factor: 49.962

6.  Expression of the μ, κ, and δ-opioid receptors and tyrosine hydroxylase in MN9D cells.

Authors:  Pengxiang Tian; Weibo Shi; Jie Liu; Jie Wang; Chunling Ma; Qian Qi; Bin Cong; Yingmin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

Review 8.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

9.  Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Authors:  Candy S Hwang; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2018-11-20       Impact factor: 3.641

10.  Efficacious Vaccine against Heroin Contaminated with Fentanyl.

Authors:  Candy S Hwang; Lauren C Smith; Yoshihiro Natori; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2018-03-23       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.